Cited by 830Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona, Kuhlmann, Georgiana L., Han, Moon, Goldberg, Jonathan S., Settleman, Jeffrey, Iafrate, A. John, Engelman, Jeffrey A., Haber, Daniel A., Johnson, Bruce E., Lynch, Thomas J.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.8494

Open this paper in CoChat — free account

Abstract

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms. PATIENTS AND METHODS: Chemotherapy-naïve patients with advanced NSCLC with >or= 1 clinical characteristic associated with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21. Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity. The primary outcome was response rate. RESULTS: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%). EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21% of mutation-positive cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q. Thirty-one patients received gefitinib. The response rate was 55% (95% CI, 33 to 70) and median progression-free survival was 9.2 months (95% CI, 6.2 to 11.8). Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis. Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification. CONCLUSION: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance. This strategy should be compared with combination chemotherapy, the current standard of care.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.8494

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citation
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citation

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 301–400 of 830

Tyrosine Kinase Inhibitors in Lung Cancer
Thomas, A., Rajan, A., & Giaccone, G. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.001 · Cited by 45
Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
Nurwidya, F., Takahashi, F., & Takahashi, K. (2016) · Journal of Natural Science Biology and Medicine · doi:10.4103/0976-9668.184695 · Cited by 43
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43
Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status
Huang, Q., Lü, L., Dercle, L., Lichtenstein, P., Li, Y., Yin, Q., Zong, M., Schwartz, L. H., & Zhao, B. (2017) · Journal of medical imaging · doi:10.1117/1.jmi.5.1.011005 · Cited by 42
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
Xu, J., Han, Y., Duan, H. Q., Gao, E., Zhang, Y., Liu, X., Zhang, J. S., Toschi, L., Galetta, D., Azzariti, A., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0512-1 · Cited by 42
The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer
Pal, S. K., Figlin, R. A., & Reckamp, K. L. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.049 · Cited by 43
The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR‐TKI
Huang, Z., Wang, Z., Bai, H., Wu, M., An, T., Zhao, J., Yang, L., Duan, J., Zhuo, M., Wang, Y., et al. (2012) · Thoracic Cancer · doi:10.1111/j.1759-7714.2012.00133.x · Cited by 42
Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy
Nishino, M., Dahlberg, S. E., Cardarella, S., Jackman, D. M., Rabin, M. S., Ramaiya, N. H., Hatabu, H., Janne, P. A., & Johnson, B. E. (2013) · Cancer · doi:10.1002/cncr.28290 · Cited by 42
Self-citation
Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated Slug expression
Qiu, W.-L., Tseng, A.-J., Hsu, H.-Y., Hsu, W.-H., Lin, Z., Hua, W.-J., & Lin, T. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.03.066 · Cited by 42
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer
Sacher, A. G., Janne, P. A., & Oxnard, G. R. (2014) · Cancer · doi:10.1002/cncr.28723 · Cited by 42
Self-citation
Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo
Wang, P., Song, L., Ge, H., Jin, P.-L., Jiang, Y., Hu, W., & Geng, N. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s68773 · Cited by 41
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.
Langer, C. J. (2011) · PubMed · Cited by 40
Management of EGFR mutated nonsmall cell lung carcinoma patients
Grigoriu, B. D., Berghmans, T., & Meert, A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00156614 · Cited by 41
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
Venugopalan, A., Lee, M.-J., Niu, G., Medina-Echeverz, J., Tomita, Y., Lizak, M. J., Cultraro, C. M., Simpson, R. M., Chen, X., Trepel, J. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11021 · Cited by 40
A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations
Deng, H., Lei, Q., Wang, C., Wang, Z., Chen, H., Wang, G., Yang, N. Y., Huang, D. A., Yu, Q., Yao, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34627-5 · Cited by 40
RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
Nishino, M., Cardarella, S., Jackman, D. M., Ramaiya, N. H., Rabin, M. S., Hatabu, H., Janne, P. A., & Johnson, B. E. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9668 · Cited by 40
Self-citation
Imaging of Lung Cancer in the Era of Molecular Medicine
Nishino, M., Jackman, D. M., Hatabu, H., Janne, P. A., Johnson, B. E., & den Abbeele, A. D. V. (2011) · Academic Radiology · doi:10.1016/j.acra.2010.10.020 · Cited by 40
Self-citation
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours
Aung, K. L., R. E. Board, Ellison, G., Donald, E. L., Ward, T. H., Clack, G., Ranson, M., Hughes, A. M., Newman, W. G., & Dive, C. (2010) · The HUGO Journal · doi:10.1007/s11568-011-9149-2 · Cited by 41
The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art
Franceschini, D., Rose, F. D., Cozzi, S., Franzese, C., Rossi, S., Finocchiaro, G., Toschi, L., Santoro, A., & Scorsetti, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102894 · Cited by 42
Non-small cell lung cancer - genetic predictors
Koudeláková, V., Kneblova, M., Trojanec, R., Drábek, J., & Hajdúch, M. (2013) · Biomedical Papers · doi:10.5507/bp.2013.034 · Cited by 39
Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas
Dahse, R., Driemel, O., Schwarz, S., Dahse, J., Kromeyer-Hauschild, K., Berndt, A., & Kosmehl, H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604875 · Cited by 39
The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
Roskoski, R. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.813015 · Cited by 39
Emerging Concepts in the Pathology and Molecular Biology of Advanced Non–Small Cell Lung Cancer
Kulesza, P., Ramchandran, K. J., & Patel, J. D. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpo66oirulfnlz · Cited by 40
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant
Qin, X., Li, Z., Yang, L., Liu, P., Hu, L., Zeng, C., & Pan, Z. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.003 · Cited by 39
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Han, J., Lee, K. H., Kim, S., Min, Y. J., Cho, E., Lee, Y., Lee, S.-H., Kim, H. Y., Lee, G. K., Nam, B., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.058 · Cited by 39
Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions
Kuan, F., Li, S., Wang, C., Lin, M., Tsai, Y., & Yang, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13815 · Cited by 40
The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC).
Xu, M. M., Xie, Y., Ni, S., & Liu, H. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.60 · Cited by 41
Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer
Cao, F., Gong, Y., Kang, X., Lu, Z., Wang, Y., Zhao, K., Miao, Z., Liao, M., & Xu, Z. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114662 · Cited by 39
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
Kim, D., Lee, S., Lee, J. S., Lee, M. A., Kang, J. H., Kim, S. Y., Shin, S. W., Kim, H.-K., & Heo, D. S. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.04.005 · Cited by 38
Molecular Diagnostics of Lung Carcinomas
Đačić, S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0625-rair.1 · Cited by 38
Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies
Tie, J., & Desai, J. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0330-0 · Cited by 38
Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
Machida, K., Eschrich, S. A., Li, J., Bai, Y., Koomen, J. M., Mayer, B. J., & Haura, E. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013470 · Cited by 38
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach
Salto‐Tellez, M., Tsao, M., Shih, J., Thongprasert, S., Lü, S., Chang, G., Au, J. S. K., Chou, T., Lee, J. S., Shi, Y.-K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227816a · Cited by 38
Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial
Benlloch, S., Botero, M. L., Bertrán-Alamillo, J., Mayo, C., Giménez-Capitán, A. A., de Aguirre, I., Queralt, C., Ramírez, J. L., y Cajal, S. R., Klughammer, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089518 · Cited by 38
Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
Romero‐Ventosa, E. Y., Blanco-Prieto, S., González-Piñeiro, A., Rodrı́guez-Berrocal, F. J., Piñeiro‐Corrales, G., & de la Cadena, M. P. (2015) · SpringerPlus · doi:10.1186/s40064-015-0891-0 · Cited by 37
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Cadranel, J. L., Zalcman, G., & Sequist, L. V. D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00179409 · Cited by 39
Self-citation
Pooled analysis of clinical outcome for EGFR TKI ‐treated patients with EGFR mutation‐positive NSCLC
Paz-Ares, L. G., Soulières, D., Moecks, J., Bāra, I., Mok, T. S. K., & Klughammer, B. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12278 · Cited by 38
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold
Ju, Y., Wu, J., Yuan, X., Zhao, L., Zhang, G., Li, C., & Qiao, R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01612 · Cited by 37
Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs
Vendrell, J. A., Mazières, J., Senal, R., Rouquette, I., Quantin, X., Pujol, J.-L., Roch, B., Bouidioua, A., Godreuil, S., Coyaud, É., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2683 · Cited by 40
C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer.
Xiao, X., Wang, S., & Long, G. (2019) · Medicine · doi:10.1097/md.0000000000016238 · Cited by 38
Biomarkers with Predictive and Prognostic Function in Non–Small Cell Lung Cancer: Ready for Prime Time?
Aggarwal, C., Somaiah, N., & Simon, G. R. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0059 · Cited by 37
Targeted therapy for lung cancer: present and future.
Aggarwal, C. (2014) · PubMed · doi:10.3978/j.issn.2224-5820.2014.06.01 · Cited by 37
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
Okamoto, I., Mitsudomi, T., Nakagawa, K., & Fukuoka, M. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010370698 · Cited by 37
Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer
Morinaga, R., Okamoto, I., Fujita, Y., Arao, T., Sekijima, M., Nishio, K., Ito, H., Fukuoka, M., Kadota, J., & Nakagawa, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00962.x · Cited by 37
Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.
Duan, H., Lu, J., Lu, T., Gao, J., Zhang, J., Xu, Y., Wang, M., Wu, H., Liang, Z., & Liu, T. (2015) · PubMed Central · Cited by 37
The liquid biopsy in lung cancer
Ansari, J., Yun, J. W., Kompelli, A. R., Moufarrej, Y. E., Alexander, J. S., Herrera, G. A., & Shackelford, R. E. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.127 · Cited by 37
Getting Folded: Chaperone Proteins in Muscle Development, Maintenance and Disease
Smith, D. A., Carland, C. R., Guo, Y., & Bernstein, S. I. (2014) · The Anatomical Record · doi:10.1002/ar.22980 · Cited by 37
Targeting SALL4 by entinostat in lung cancer
Yong, K. J., Li, A., Ou, W.-B., Hong, C. K. Y., Zhao, W., Wang, F., Tatetsu, H., Yan, B., Qi, L., Fletcher, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12251 · Cited by 41
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
Miyauchi, E., Inoue, A., KOBAYASHI, K. P., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Saijo, Y., Yoshizawa, H., et al. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv054 · Cited by 36
Gefitinib in Non Small Cell Lung Cancer
Costanzo, R., Piccirillo, M. C., Sandomenico, C., Carillio, G., Montanino, A., Daniele, G., Giordano, P., Bryce, J., Feo, G. D., Maïo, M. D., et al. (2011) · BioMed Research International · doi:10.1155/2011/815269 · Cited by 37
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
Belani, C. P., Goss, G. D., & Blumenschein, G. R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.05.009 · Cited by 39
Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications
Mayo, C., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Costa, C., & Rosell, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.54 · Cited by 36
BRAF Inhibitors and Melanoma
Flaherty, K. T. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e5357 · Cited by 36
MALVA: Genotyping by Mapping-free ALlele Detection of Known VAriants
Denti, L., Previtali, M., Bernardini, G., Schönhuth, A., & Bonizzoni, P. (2019) · iScience · doi:10.1016/j.isci.2019.07.011 · Cited by 37
Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients
Kim, H. J., Oh, S. Y., Kim, W. S., Kim, S. J., Yoo, G. H., Kim, W. D., & Lee, K. Y. (2012) · Oncology Letters · doi:10.3892/ol.2012.950 · Cited by 35
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients
Sun, J., Won, Y., Kim, S. T., Kim, J. H., Choi, Y., Lee, J., Park, Y. H., Ahn, J. S., Park, K., & Ahn, M. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0928-2 · Cited by 36
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild‐type nonsmall cell lung cancer treated with EGFR‐tyrosine kinase inhibitors
Chang, M. H., Ahn, H. K., Lee, J., Jung, C. K., Choi, Y., Park, Y. H., Ahn, J. S., Park, K., & Ahn, M. (2010) · Cancer · doi:10.1002/cncr.25560 · Cited by 36
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1
Gately, K. A., O’Flaherty, J. D., Cappuzzo, F., Pirker, R., Kerr, K. M., & O'Byrne, K. J. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200275 · Cited by 35
Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer
Wang, H., Zhang, B., Chen, D., Xia, W., Zhang, J., Wang, F., Xu, J., Zhang, Y., Zhang, M., Zhang, L., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0150-9 · Cited by 35
Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
Wang, N., Wang, L., Meng, X., Wang, J., Zhu, L., Liu, C., Li, S., Li, Z., Yang, Z., Xing, L., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6803 · Cited by 36
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
Provencio, M., Serna‐Blasco, R., Franco, F., Calvo, V., Royuela, A., Auglytė, M., Sánchez-Hernández, A., Campayo, M. D. J., Girón, C. G., Dómine, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.031 · Cited by 35
Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: Molecular modeling studies
Hamdi, A., El-Shafey, H. W., Othman, D. I. A., El‐Azab, A. S., Alsaif, N. A., & Abdel‐Aziz, A. A. ‐. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105710 · Cited by 35
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib
Nishino, M., Dahlberg, S. E., Fulton, L. E., Digumarthy, S. R., Hatabu, H., Johnson, B. E., & Sequist, L. V. D. (2016) · Academic Radiology · doi:10.1016/j.acra.2015.11.005 · Cited by 35
Self-citation
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017) · Cancers · doi:10.3390/cancers9040033 · Cited by 36
AZD9291 in EGFR -Mutant Advanced Non-Small-Cell Lung Cancer Patients
Remon, J., & Planchard, D. (2015) · Future Oncology · doi:10.2217/fon.15.250 · Cited by 33
Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing
Moskalev, E. A., Stöhr, R., Rieker, R. J., Hebele, S., Fuchs, F. S., Sı̂rbu, H., Mastitsky, S., Boltze, C., König, H., Agaimy, A., et al. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1376-6 · Cited by 34
Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment
Azuma, K., Okamoto, I., Kawahara, A., Taira, T., Nakashima, K., Hattori, S., Kinoshita, T., Takeda, M., Nakagawa, K., Takamori, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822eeba2 · Cited by 32
EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review
Tsiambas, E., Lefas, A. Y., Georgiannos, S. N., Ragos, V., Fotiades, P. P., Grapsa, D., Σταματελόπουλος, Α., Kavantzas, N., Patsouris, E., & Syrigos, K. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.005 · Cited by 38
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages
Yang, M., Topaloĝlu, Ü., Petty, W. J., Pagni, M., Foley, K. L., Grant, S. C., Robinson, M., Bitting, R. L., Thomas, A., Alistar, A. T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0468-1 · Cited by 34
Rare deleterious germline variants and risk of lung cancer
Liu, Y., Xia, J., McKay, J., Tsavachidis, S., Xiao, X., Spitz, M. R., Cheng, C., Byun, J., Wei, H., Li, Y., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00146-7 · Cited by 35
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines
Galetti, M., Alfieri, R. R., Cavazzoni, A., Monica, S. L., Bonelli, M. A., Fumarola, C., Mozzoni, P., Palma, G. D., Andreoli, R., Mutti, A., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.033 · Cited by 34
GATA2 is Epigenetically Repressed in Human and Mouse Lung Tumors and Is Not Requisite for Survival of KRAS Mutant Lung Cancer
Tessema, M., Yingling, C. M., Snider, A. M., Do, K., Juri, D. E., Picchi, M. A., Zhang, X., Liu, Y., Leng, S., Tellez, C. S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000165 · Cited by 33
The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer
Olayan, A. A., Hussaini, H. A., & Jazieh, A. R. (2012) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2012.09.004 · Cited by 36
Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study
Sun, Y. K., Wu, Y.-L. L. C., Zhou, C., Zhang, L., Zhang, L., Liu, X.-Y., Yu, S., Jiang, G., Li, K., Qin, S., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.10.015 · Cited by 33
Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors
Zhang, L., Yang, Y., Zhou, H.-J., Zheng, Q., Li, Y., Zheng, S., Zhao, S., Chen, D., & Fan, C. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.026 · Cited by 33
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer
Vendetti, F. P., Topper, M. J., Huang, P., Dobromilskaya, I., Easwaran, H., Wrangle, J. M., Baylin, S. B., Poirier, J. T., & Rudin, C. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2695 · Cited by 34
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
Lazar, V., Rubin, E., Depil, S., Yudi Pawitan, Y., Martini, J., Gómez-Navarro, J., Yver, A., Kan, Z., Dry, J. R., Kehren, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3741 · Cited by 32
Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis
Li, Z., Zhang, Y., Bao, W., & Jiang, C. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0312-2 · Cited by 32
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
Woo, H. S., Ahn, H. K., Lee, H. Y., Park, I., Kim, Y. S., Hong, J., Sym, S. J., Park, J., Lee, J. H., Shin, D. B., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0146-x · Cited by 32
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
Takeda, M., Okamoto, I., Tsurutani, J., Oiso, N., Kawada, A., & Nakagawa, K. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys042 · Cited by 32
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation
Zhao, B.-X., Wang, J., Song, B., WEI, H., Lv, W., TIAN, L.-M., Li, M., & Lv, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3058 · Cited by 32
Novel agents in development for advanced non-small cell lung cancer
Stinchcombe, T. E. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014532510 · Cited by 32
Detection of low-level EGFR T790M mutation in lung cancer tissues
Oh, J. E., An, C. H., Yoo, N. J., & Lee, S. H. (2011) · Apmis · doi:10.1111/j.1600-0463.2011.02738.x · Cited by 31
Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers
Yang, Z., Ding, X., Pen, L., Mei, L., & Liu, T. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.8.3451 · Cited by 32
Cryoablation Combined with Molecular Target Therapy Improves the Curative Effect in Patients with Advanced Non-Small Cell Lung Cancer
Gu, X., Jiang, Z., & Fang, W. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900516 · Cited by 32
Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis
Rau, K., Chen, H.-K., Shiu, L., Chao, T.-L., Lo, Y.-P., Wang, C., Lin, M., & Huang, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040524 · Cited by 31
Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
Hong, D., Zhang, G., Zhang, X., & Liang, X. (2016) · Medicine · doi:10.1097/md.0000000000003008 · Cited by 30
TUSC3 induces autophagy in human non-small cell lung cancer cells through Wnt/β-catenin signaling
Peng, Y., Cao, J., Yao, X., Wang, J., Zhong, M., Gan, P., & Li, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17674 · Cited by 30
Retracted
Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides
Liu, J., Bhadra, M., Sinnakannu, J. R., Yue, W. L., Tan, C. W., Rigo, F., Ong, S. T., & Roca, X. (2017) · Oncotarget · doi:10.18632/oncotarget.20658 · Cited by 30
Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
Floros, K. V., Lochmann, T. L., Hu, B., Monterrubio, C., Hughes, M. T., Wells, J. D., Morales, C. B., Ghotra, M. S., Costa, C., Souers, A. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717820115 · Cited by 30
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
Alcon, C., Zañudo, J. G. T., Albert, R., Wagle, N., Scaltriti, M., Letai, A. G., Samitier, J., & Montero, J. (2021) · Cells · doi:10.3390/cells10071659 · Cited by 32
Squamous Non–small Cell Lung Cancer as a Distinct Clinical Entity
Oliver, T. G., Patel, J. C., & Akerley, W. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182a0e850 · Cited by 29
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26
EGFR-targeting agents in oncology
Garofalo, S., Rosa, R., Bianco, R., & Tortora, G. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.8.889 · Cited by 29
Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status
Bhatt, A., Pai, R., Rebekah, G. J., Nehru, G., Dhananjayan, S., Samuel, A., Singh, A. K., Joel, A., Korula, A., & Chacko, R. (2013) · Indian Journal of Cancer · doi:10.4103/0019-509x.117016 · Cited by 28
Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Ki, Y., Lee, H. Y., Ahn, M., Choi, Y., Lee, J. H., Park, K., & Lee, K. S. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.11.002 · Cited by 29
Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition.
Liu, M., Zhou, C., & Zheng, J. (2015) · Europe PMC (PubMed Central) · Cited by 28
Individualized therapy in non-small-cell lung cancer: future versus current clinical practice
Perez-Soler, R. (2009) · Oncogene · doi:10.1038/onc.2009.200 · Cited by 30
Small-molecule inhibitors of the human epidermal receptor family
Carter, C. A., Kelly, R. J., & Giaccone, G. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903373343 · Cited by 28
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation
Zou, M., Xia, S., Zhuang, L., Han, N., Chu, Q., Chao, T., Peng, P., Chen, Y., Gui, Q., & Yu, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1895 · Cited by 28

Authors: Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., Kuhlmann, G. L., Han, M., Goldberg, J. S., Settleman, J., Iafrate, A. J., Engelman, J. A., Haber, D. A., Johnson, B. E., & Lynch, T. J.
Affiliations: Brigham and Women's Hospital (US)
From the Massachusetts General Hospital Cancer Center; Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital; Department of Pathology, Massachusetts General Hospital; Department of Biostatistics, Massachusetts General Hospital, Boston; Harvard Medical School/Partners Health Care Center for Genetics and Genomics, Cambridge, MA; University of Washington, Seattle, WA; Sarah Cannon Research Institute, Nashville, TN; Fletcher Allen Health Care, Burlington, VT; Fairfax-Northern...
ORCID: Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Spira, Alexander
Evans, Tracey L.
Muzikansky, Alona
Han, Moon
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2442-2449
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.8494
OpenAlex: W2101329867
Cited by: 820
References: 46
Citations by year: 2026: 4 · 2025: 14 · 2024: 9 · 2023: 11 · 2022: 20 · 2021: 22 · 2020: 34 · 2019: 29 · 2018: 51 · 2017: 51 · 2016: 54 · 2015: 57 · 2014: 68 · 2013: 69 · 2012: 60
FWCI: 81.10
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, non-small cell lung cancer, EGFR mutation, first-line therapy, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, T790M mutation, MET amplification, progression-free survival, response rate, pneumonitis, genotype-directed therapy
MeSH terms: Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prospective Studies, Quinazolines, Survival Rate, Central Nervous System Neoplasms, Treatment Outcome, In Situ Hybridization, Fluorescence, Carcinoma, Large Cell, Disease-Free Survival, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks